Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study

D Luftner; MK Welslau; R Liersch; M Deryal; Cosima Brucker; J Rauh; A Welt; M Zaiss; J Sahlmann; L Houet; C Vannier; K Potthoff; NW Marschner

Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study

D Luftner, MK Welslau, R Liersch, M Deryal, Cosima Brucker, J Rauh, A Welt, M Zaiss, J Sahlmann, L Houet, C Vannier, K Potthoff, NW Marschner

Department of Gynaecology and Obstetrics

Research output: Contribution to journal › published Abstract (Journal) › peer-review

Original language	English
Journal	ANNALS OF ONCOLOGY
Volume	30
Publication status	Published - 2019
Event	44th Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, SPAIN Duration: 27 Sept 2019 → 1 Oct 2019

Cite this

Luftner, D., Welslau, MK., Liersch, R., Deryal, M., Brucker, C., Rauh, J., Welt, A., Zaiss, M., Sahlmann, J., Houet, L., Vannier, C., Potthoff, K., & Marschner, NW. (2019). Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study. ANNALS OF ONCOLOGY , 30.

Luftner, D ; Welslau, MK ; Liersch, R et al. / Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study. In: ANNALS OF ONCOLOGY 2019 ; Vol. 30.

@article{01da70351a864e26be3a4912481b1aa1,

title = "Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study",

author = "D Luftner and MK Welslau and R Liersch and M Deryal and Cosima Brucker and J Rauh and A Welt and M Zaiss and J Sahlmann and L Houet and C Vannier and K Potthoff and NW Marschner",

year = "2019",

language = "English",

volume = "30",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

note = "44th Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 27-09-2019 Through 01-10-2019",

}

Luftner, D, Welslau, MK, Liersch, R, Deryal, M, Brucker, C, Rauh, J, Welt, A, Zaiss, M, Sahlmann, J, Houet, L, Vannier, C, Potthoff, K & Marschner, NW 2019, 'Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study', ANNALS OF ONCOLOGY , vol. 30.

Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study. / Luftner, D; Welslau, MK; Liersch, R et al.
In: ANNALS OF ONCOLOGY , Vol. 30, 2019.

Research output: Contribution to journal › published Abstract (Journal) › peer-review

TY - JOUR

T1 - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study

AU - Luftner, D

AU - Welslau, MK

AU - Liersch, R

AU - Deryal, M

AU - Brucker, Cosima

AU - Rauh, J

AU - Welt, A

AU - Zaiss, M

AU - Sahlmann, J

AU - Houet, L

AU - Vannier, C

AU - Potthoff, K

AU - Marschner, NW

PY - 2019

Y1 - 2019

M3 - published Abstract (Journal)

SN - 0923-7534

VL - 30

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Y2 - 27 September 2019 through 1 October 2019

ER -

Luftner D, Welslau MK, Liersch R, Deryal M, Brucker C, Rauh J et al. Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study. ANNALS OF ONCOLOGY . 2019;30.